Sri Harsha Tella

Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma

Shruti Chandra, Thorvardur Ragnar Halfdanarson, Erin E. Carlson, Kari G. Rabe et autres

Pancreatic neuroendocrine neoplasm (panNEN) is a rare malignancy and the second most common type of pancreatic cancer after pancreatic ductal adenocarcinoma (PDAC), but its etiology is poorly understood. We investigated whether the risk factors of panNEN are concordant with those known for …

us, jp (code pays fourni par la source)

Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States

Michael Harrison Storandt, Sri Harsha Tella, Mikolaj A. Wieczorek, David O. Hodge et autres

Background: Identifying the projected incidence of hepatobiliary cancers and recognizing patient cohorts at increased risk can help develop targeted interventions and resource allocation. The expected incidence of subtypes of hepatobiliary cancers in different age groups, races, and genders remains unknown. Methods: Historical …

us (code pays fourni par la source)

THU535 Anti-angiogenic Multi-kinase Inhibitor In NUTM1 Rearranged Carcinoma Of Thyroid

Sri Harsha Tella, John C. Morris, Michael Rivera, Sounak Gupta et autres

Abstract Disclosure: S. Tella: None. J.C. Morris: None. M. Rivera: None. S. Gupta: None. M.M. Ryder: None. Introduction: NUT carcinoma is a rare subtype of squamous cell carcinoma defined by NUTM1 rearrangements encoding NUT-fusion oncoproteins with a very dismal prognosis. Recent data …

us (code pays fourni par la source)

Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review

Charan Thej Reddy Vegivinti, Praneeth Reddy Keesari, Sindhusha Veeraballi, Catarina Maia et autres

Dysregulation of the innate immune system and inflammatory-related pathways has been implicated in hematopoietic defects in the bone marrow microenvironment and associated with aging, clonal hematopoiesis, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). As the innate immune system and its pathway …

us, in (code pays fourni par la source)

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma

Sri Harsha Tella, Nathan R. Foster, Qian Shi, Tran Nguyen et autres

BACKGROUND: We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC). METHODS: A total of 28 patients (27 were evaluable) with advanced BTCs who …

us (code pays fourni par la source)

A glimpse into the future of esophageal carcinoma in the United States: predicting the future incidence until 2040 based on the current epidemiological data

Sri Harsha Tella, Kristin C. Mara, Sakti Chakrabarti, Zhaohui Jin et autres

Background: Esophageal carcinoma is the sixth most common cause of death worldwide. With the changing paradigm of esophageal carcinoma, we sought to estimate the future burden of esophageal carcinoma by histology, age, sex, and race, which could help plan prevention, control, and …

us (code pays fourni par la source)

A glimpse into the future of hepatocellular carcinoma (HCC): Predicting the future incidence based on the current epidemiological data.

Sri Harsha Tella, Mikolaj Wieczorek, David O. Hodge, Amit Mahipal

615 Background: Accounting for 90% of primary liver cancers, HCC is the fourth-most common cause of cancer-related deaths in the United States. While the vaccination against hepatitis B and awareness on hepatitis C transmission possibly decreased the incidence of HCC in Eastern …

us (code pays fourni par la source)

A glimpse into the future of cholangiocarcinoma: Predicting the future incidence based on the current epidemiological data.

Sri Harsha Tella, Mikolaj Wieczorek, David O. Hodge, Amit Mahipal

616 Background: Cholangiocarcinoma (CCA) is an aggressive, heterogenous group of neoplasms that arise from the epithelial lining of bile ducts that have dismal poor prognosis. A recent epidemiological study in the United States demonstrated a steady increase in the incidence of cholangiocarcinoma …

us (code pays fourni par la source)

Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations

Michael Harrison Storandt, Amit Mahipal, Sri Harsha Tella, Anuhya Kommalapati et autres

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Most patients with HCC have advanced disease at initial diagnosis, and sorafenib has been the only systemic treatment option for more than a decade in patients with advanced, unresectable …

us (code pays fourni par la source)

An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma

Sri Harsha Tella, Amit Mahipal

Introduction The combination of gemcitabine and cisplatin remains the standard-of-care first-line therapeutic option in patients with the unresectable disease based on the encouraging phase II and phase III trials (ABC-02). Recently, the combination of durvalumab, gemcitabine, and cisplatin has shown modest but …

us (code pays fourni par la source)

Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)

Haris Hatic, Shealeigh A. Inselman, Jonathan Inselman, Anuhya Kommalapati et autres

us (code pays fourni par la source)

Disparities in overall survival (OS) outcomes based on treating facility volume in pancreatic neuroendocrine tumors.

Sri Harsha Tella, Anuhya Kommalapati, Aakash P. Desai, Patrick Walsh McGarrah et autres

150 Background: Pancreatic neuroendocrine tumors (pNETs) comprise less than 5% of all pancreatic tumors and 7% of all neuroendocrine tumors (NETs). There has been considerable progress in understanding the biology of pNETs and numerous therapeutic options emerged, especially with the collaboration of …

us (code pays fourni par la source)